Citrini Research
3 storiesCitrini Research is a research firm that publishes investment themes and partners with AI companies on research. It worked with Anthropic to have an internal research model autonomously design minibinders against scorpion neurotoxins over about 64 hours, with 17 of 211 designs meeting binding criteria. Citrini then argued AI-driven drug discovery will benefit life sciences investing, and said blockchain-based agentic finance creates a new paradigm for crypto investing.
Related topics
Anthropic worked with Citrini Research to have an internal research model autonomously design minibinders against scorpion neurotoxins over about 64 hours. Adaptyv Bio and Twist Bioscience tested 211 designs, and 17 met the binding criteria; all designs and data were released. Scorpion stings cause over 3,250 deaths a year, and the neglected disease attracts little commercial investment.
Citrini Research, after testing Anthropic's Claude Science, argues that AI-driven drug discovery will accelerate, benefiting life sciences companies. The firm is bullish on the sector's investment opportunities.
Citrini Research argues that agentic finance built on blockchains has created a new paradigm of fundamental crypto investing, potentially transforming how investors approach the asset class.
That is everything
The A.I. Daily
Claude designs protein binders against scorpion neurotoxins; 17 of 211 designs meet criteria